Table 2.
Clinicopathological features between the two groups
| pT0 group (n = 6) | Non-pT0 group (n = 105) | P-value | |
|---|---|---|---|
| Age, median (range) | 73.5 (66–77) | 66.0 (47–77) | 0.014 |
| PSA, median (range) | 20.14 (6.18–55.30) | 39.50 (4.16–261.80) | 0.126 |
| Biopsy GS (%) | 0.447 | ||
| 2–6 | 1 (16.7) | 19 (18.1) | |
| 7 | 4 (66.7) | 44 (41.9) | |
| 8–10 | 1 (16.7) | 42 (40.0) | |
| Clinical stage (%) | 0.461 | ||
| cT1c- cT2b | 0 (0.0) | 10 (9.5) | |
| cT2c | 2 (33.3) | 50 (47.6) | |
| cT3-cT4 | 4 (66.7) | 45 (42.9) | |
| Median number of positive cores on biopsy (range) | 6 (3–8) | 6 (1–13) | 0.599 |
| Median maximum tumor length (range) | 10.0 mm (3.0–21.0) | 11.0 mm (0.5–25.0) | 0.806 |
| Median duration of NHT (range) | 6 months (3–12) | 3 months (3–30) | 0.144 |
| Median (PSA) nadir after NHT (range) | 0.01 ng/ml (0.01–0.30) | 0.20 ng/ml (0.01–23.70) | 0.387 |
| Pathological stage (%) | |||
| pT0 | 6 (100.0) | ||
| pT2 | 46 (43.8) | ||
| pT3-pT4 | 46 (43.8) | ||
| N1 | 13 (12.4) | ||
| Positive resection margin | 28 (26.7) | ||
| In pT2 | 7 (15.2 %) | ||
| In pT3-pT4 | 15 (32.6 %) | ||
| In N1 | 6 (46.2 %) | ||
| Seminal vesicle invasion | 36 (34.3)) | ||
| Prostate volume, median (range) | 22.0 gm (16.0–24.1) | 24.9gm (7.5–50.0) | 0.280 |
| Tumor volume, % (range) | 0 | 20 (1–90) |
PSA prostate-specific antigen, NHT neoadjuvant hormonal therapy, GS Gleason score, NA not available